Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas
Status:
Terminated
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if administration of pasireotide LAR for one year
to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce
the serum follicle-stimulating hormone (FSH) to normal and reduce the adenoma size.